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Summary: Salivary cortisone closely correlates with serum cortisol in the unstimulated state and after 
50 minutes following synacthen stimulation. We recommend a 60min sample be used for diagnostic 
accuracy.  
 
Keywords: ACTH stimulation test, Synacthen, cosyntropin, saliva, cortisol, cortisone, adrenal 
insufficiency, Addisons  
 
Correspondence: 
Professor Richard Ross, The University of Sheffield, The Medical School, Sheffield S10 2RX. Tel: +44 
(0) 114 2159004. Fax: +44 (0) 114 2261009. E-mail: r.j.ross@sheffield.ac.uk 
 
Disclosure statement: RJR is a Director of Diurnal Group Plc. CJE, RFH, ASC, RV, BGK and NPW 
report no conflicts of interest in this work. 
 
Grants: We are grateful for support from the MRC Confidence in Concept and The Sheffield 
Children’s Hospital Charitable Trust. 
 
Registered EudraCT number: 2009-013355-29 and 2012-003241-15 
 
Abstract 
Context: Salivary cortisone reflects serum cortisol levels, is more sensitive than salivary cortisol at 
lower values of serum cortisol and is non-invasive. 
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Objective: To investigate the relationship between serum cortisol and salivary cortisol and cortisone 
following low and high-dose synacthen. 
Design and Setting: Prospective pharmacodynamic studies in clinical research facilities. 
Participants and Intervention: 35 dexamethasone-suppressed, healthy adult males underwent an 
intravenous synacthen test: N=23 low-dose (1mcg), N=12 high-dose (250mcg). Paired serum and 
salivary samples were taken at 15 sampling points over 120 minutes. 
Main outcome measure: Serum cortisol and salivary cortisol and cortisone were analyzed for 
correlations and by a mixed effects model. 
Results: At baseline the correlation between serum cortisol and salivary cortisol was weak with many 
samples undetectable (r=0.45, NS), but there was a strong correlation with salivary cortisone (r=0.94, 
p<0.001). Up to 50 minutes following synacthen the correlation coefficient between serum cortisol and 
salivary cortisol and cortisone was <0.8, but both had a stronger correlation at 60 minutes (salivary 
cortisol r=0.89, p<0.001, salivary cortisone r=0.85, p<0.001). The relationship was examined 
excluding samples in the dynamic phase (baseline to 60 minutes). Salivary cortisol and cortisone 
showed a close relationship to serum cortisol. Salivary cortisone showing the stronger correlation: 
Salivary cortisol r=0.82, p<0.001, salivary cortisone r=0.96, p<0.001. 
Conclusion: Following synacthen, both salivary cortisol and cortisone reflect serum cortisol levels but 
there is a lag in their rise up to 60mins. The results support further research for possible future use of 
a 60min salivary cortisone measurement during the synacthen test.  
 
Introduction 
Measurement of salivary cortisol is becoming routine in some clinics for the assessment of adrenal 
function. Late-night salivary cortisol testing is now recommended as a first-line diagnostic test in 
Cushing’s syndrome 1, and there are reports of its use in the diagnosis of adrenal insufficiency 2-10. 
Advocates of salivary measurements favor its convenience and potential cost savings over serum 
sampling. It is non-invasive, painless, has no requirement for clinic attendance, reflects serum free 
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cortisol and there is less risk of false positive results, generated by the cortisol stress response to 
venipuncture, when testing for Cushing’s disease. Recent evidence suggests that salivary cortisone is 
a better reflection of serum total and free cortisol than salivary cortisol 2,11-13. Serum free cortisol and 
salivary cortisol are rapidly oxidized to inactive cortisone, by 11β-hydroxysteroid dehydrogenase type 
2 (11β-HSD-2), which is responsible for the large difference in the proportion of salivary 
cortisol:cortisone (1:6) compared with that in serum (4:1) 11. Salivary cortisone reflects serum cortisol 
levels both under physiological conditions 2 and after administration of hydrocortisone, with 94% of 
the variability in salivary cortisone attributable to changes in serum cortisol 11,12. Salivary cortisone is 
more sensitive at low serum cortisol levels than salivary cortisol making it better suited for the 
detection of adrenal insufficiency 2,5,8,12.  
 Stimulation of the adrenal cortex with synthetic (1-24) ACTH (synacthen) is the standard 
diagnostic test for adrenal insufficiency 9,14,15. The test involves administration of 250 mcg of 
synacthen, a supraphysiological dose. The low dose synacthen test (most commonly 1 mcg) is used 
by some clinicians, as it is thought to more closely mimic a physiological stress stimulus to the 
adrenal cortex 14. Results of meta-analyses do not show significant superiority of one test over 
another and both doses are used in clinical practice 16-20. 
 The measurement of salivary cortisol has been used after stimulation, with different doses of 
synacthen, in both healthy volunteers and patients 3-6,8,10. The results support the use of salivary 
sampling after synacthen, particularly in groups with low serum steroid binding-protein levels and 
women on estrogens 10,12,21. There is limited data on the use of salivary cortisone following synacthen 
stimulation 5,8,12. We report the relationship of serum cortisol, salivary cortisol and salivary cortisone 
following administration of low and high dose synacthen and demonstrate the importance of sample 
timing. 
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Subjects and Methods 
Three prospective pharmacodynamic studies were conducted at the Clinical Research Facilities of 
Sheffield Children’s NHS Foundation Trust and Sheffield Teaching Hospitals NHS Trust. The studies 
recruited 35 healthy adult males, aged 19-46 years (median 22, IQR 21.5-23.5), BMIs (19.1-29.4 
kg/m2 (median 23.2, IQR 21.8-24.4). Volunteers were excluded if they smoked, had been diagnosed 
with an endocrinopathy, intra-cranial or adrenal pathology, asthma, allergic rhinitis, anemia, peptic 
ulcer disease, gastrointestinal bleed or dyspepsia, experienced a severe allergic reaction or any 
hypersensitivity to synacthen, were on any regular or prescribed medication, received any formulation 
of corticosteroid in the previous three months or had ever had a course of oral corticosteroids lasting 
more than one month. Study 1 was approved by Leeds (West) Research Ethics Committee and 
studies 2 and 3 by London-Hampstead Research Ethics Committee. Written informed consent was 
given by all participants. 
 
Procedures: The studies were conducted in a similar fashion. All visits commenced between 08.30 
and 09.30. Following basic demographic and auxological data collection volunteers had an 
intravenous cannula sited and then rested for 30 minutes. They were asked to remain supine for the 
duration of the testing. Following baseline samples volunteers received intravenous synacthen (250 
mcg/ml vials, Mallinckrodt Specialty Pharmaceuticals Ireland Ltd, Dublin, Ireland). In the low-dose 
studies volunteers (N=23) received 1 mcg of intravenous synacthen by diluting 0.5 ml of 250 mcg/ml 
solution in 500 ml of 0.9% saline, mixing thoroughly and administering 4 ml of the resultant solution 
(low-dose test). In the high-dose study (N=12) volunteers received 250 mcg of synacthen (high-dose 
test). Paired blood and saliva samples were taken at the following times (administration of synacthen 
at 0 minutes): -1, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, and 120 minutes, with replacement of the 15 
minute sample with a 2 minute sample in the high-dose study. All blood samples were taken from the 
indwelling cannula. Saliva sampling was performed using the passive drool technique, which involves 
volunteers spitting or drooling down a straw into a salicap tube (IBL Hamburg, Germany) for 
collection. Ten minutes before the first samples were taken volunteers were asked to rinse their 
mouth thoroughly with water and did not eat or drink anything (other than water) until conclusion of 
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the study visit. Saliva sampling was done at the same time point as serum sampling with subject 
initiating the drool at the same time as the syringe was connected to the cannula to withdraw the 
discard before taking the serum sample. To provide a uniform baseline all volunteers were 
dexamethasone suppressed prior to each visit with 1 mg on retiring the night before and a further 1 
mg after breakfast on the morning of the test. Successful dexamethasone suppression was 
established by undetectable ACTH and cortisol at baseline (-1 minute sample).  
 
Assays: Serum cortisol samples were analyzed using the Abbott Architect chemiluminescent 
microparticle immunoassay (Abbott Diagnostics Ltd, Berkshire, UK). The minimum detectable dose of 
cortisol for the assay is <0.8 mcg/dL (22 nmol/L) with a functional sensitivity of <1 mcg/dL (27 
nmol/L). It has an assay precision of 4.0% total CV for serum samples <3 to 35 mcg/dL (82 to 965 
nmol/L). The quoted cross-reactivity with cortisone is 2.7%. Salivary cortisol and cortisone analysis 
was performed by a modified liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay 
using a Waters Xevo TQ-MS mass spectrometer and a Waters Acquity LC system with an 
electrospray source operated in positive-ionization mode 22. Lower limits of quantitation were 0.03 
mcg/dL (0.8 nmol/L) for both salivary cortisol and salivary cortisone and intra-assay CVs of 9.3% and 
7.9%, and inter-assay CVs of 9.7% and 10.3% at <0.1-1.9 mcg/dL (1.8-52.2 nmol/L) of salivary 
cortisol and 0.1-3.5 mcg/dL (3.6-96 nmol/L) of cortisone, respectively. 
 
Statistical analysis: 
T-tests were used to compare the salivary cortisol and salivary cortisone Cmax (peak serum 
concentration achieved) and Tmax (time at which peak serum concentration achieved) following low-
dose coyntropin and p<0.05 considered significant. A linear mixed-effects model relating the 
(logarithm of) serum cortisol to each of (logarithm of) salivary cortisol and salivary cortisone was 
computed. The random effect was taken to be the subject. Pearson correlations were computed 
between (logarithm of) serum cortisol and the logarithms of each of salivary cortisone and salivary 
cortisol. Samples below the level of detection for serum and salivary assays were excluded from 
model analysis: 25 serum cortisol samples <0.8 mcg/dL (22 nmol/L), 62 salivary cortisol <0.1 mcg/dL 
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(0.8 nmol/L) and one salivary cortisone <0.1 mcg/dL (0.8 nmol/L). All computation was carried out 
using the Matlab (R2016b) numerical computing environment (Mathworks, Natick, MA). 
 
Results 
Response to synacthen (Figure 1 and Table 1): Salivary cortisol and cortisone demonstrated 
similar time concentration profiles to serum cortisol following stimulation with high-dose (250 mcg) 
and low-dose (1 mcg) synacthen. The rise in corticosteroids showed a different pattern after high-
dose compared with low-dose synacthen with the median serum cortisol Cmax higher (22 and 14 
mcg/dL respectively (615 and 386 nmol/L)), and Tmax later (120 and 30 mins respectively). There 
was a difference in Tmax for salivary cortisol and cortisone following low-dose synacthen 30 vs 40 
mins respectively (p=0.001). The mean serum concentration of cortisol following 250 mcg synacthen 
at 30 minutes was 15 mcg/dL (407 nmol/L) (SD 44, range 349-477) and at 60 minutes 19 mcg/dL 
(511 nmol/l) (SD 49, range 433-581). Salivary cortisol was <0.8 nmolL in 16.2% of samples at low 
serum cortisol levels, whereas salivary cortisone was detectable in all but one sample, which was 
collected at 5 minutes with a corresponding salivary cortisol of <0.8 nmol/L and serum cortisol of 0.9 
mcg/dL (25 nmol/L). 
 
Relationship between serum and salivary observations (Figure 2): Linearity between variables 
was achieved after log transformation and both salivary cortisol and cortisone correlated with serum 
cortisol, however it was evident that at the early time points, following synacthen, serum cortisol was 
relatively higher than the salivary measurements. We therefore examined the relationship excluding 
the samples between baseline and 60 minutes. In this analysis both salivary cortisol and salivary 
cortisone showed a close relationship to serum cortisol, with salivary cortisone showing the stronger 
correlation: Salivary cortisol r=0.82, p<0.001 and salivary cortisone r=0.96, p<0.001. Our mixed 
effects model derived from these data gave the line intercept for (log10) salivary cortisol of 2.17 with a 
slope of 0.387 and 1.23 for (log10) salivary cortisone with a slope of 0.823. The correlation between 
the fixed effects prediction for the salivary cortisol model was 0.82 and for the salivary cortisone 
model, 0.96 (p<0.001). 
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 We further examined the relationship between salivary cortisone and serum cortisol at each 
individual time point (Figure 3). From these data it can be seen that, after the baseline sample and up 
to 30 minutes, the value of serum cortisol falls above the regression line for the fixed effects model. At 
40 minutes the serum cortisol is closer, but the majority of values lie above the regression line, and 
from 50 minutes to 120 minutes the serum cortisol falls on or near the regression line. When we plot 
the correlation between salivary cortisol and salivary cortisone with serum cortisol for the individual 
time points (Figure 4), we can see that at time zero there is a very poor correlation for salivary cortisol 
(r=0.45, NS) because many samples fall below the lower limit of detection, but for salivary cortisone 
there was a strong correlation (r=0.94, p<0.001). After synacthen the correlation between serum 
cortisol and salivary cortisol and salivary cortisone fell and then rose so that after 50 minutes the 
correlation was r >0.8, p<0.001 for both.  
 
Discussion 
Our results show that following synacthen, salivary cortisone reflects serum cortisol levels but 
importantly there was a lag in the rise in salivary cortisone such that up to 50 minutes salivary 
cortisone was lower than would be predicted from serum cortisol values. Salivary cortisone showed a 
stronger correlation with serum cortisol than salivary cortisol primarily because at low levels of serum 
cortisol, salivary cortisol was <0.8 nmol/L. The results support the use of salivary cortisone 
measurement during the synacthen test but suggest that rather than using a 30 minute sample, as is 
commonly used with serum cortisol, the measurement of salivary cortisone at 60 minutes may be a 
more reliable reflection of serum cortisol.  
 The response of serum cortisol to both 250 mcg and 1 mcg synacthen is consistent with 
previous reports and thus demonstrates a reliable and reproducible response 23-25. Exposure to two 
doses of dexamethasone would not be expected to suppress the adrenal gland but reduces the basal 
cortisol level and therefore the peak serum cortisol achieved by our healthy subjects. Even with a 
modest early morning baseline of 4 mcg/dL (110 nmol/L) all subjects would have reached a peak 
cortisol of more than 18 mcg/dL (500 nmol/L) at 60 minutes and more than 16 mcg/dL (450 nmol/L) at 
30 minutes (our local assay-derived diagnostic threshold).  
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There are concerns that, in view of the slower clearance of salivary compared with serum 
cortisol following IV and oral hydrocortisone administration, prior treatment with hydrocortisone may 
interfere with the interpretation of the synacthen test if glucocorticoid response is measured in saliva 
26
. Our previous work demonstrated that the relationship between serum cortisol and salivary 
cortisone is the same under physiological conditions as it is after oral or iv hydrocortisone and after 
synacthen 11. Prior administration of hydrocortisone may therefore impact on the test’s interpretability 
but need not prevent the use of salivary cortisone, rather than serum cortisol, for interpretation. 
Peak serum cortisol was achieved at 30 minutes following low-dose synacthen but continued 
to rise to the last sampling point at 120 minutes after 250 mcg synacthen. A similar pattern of 
response was seen with salivary cortisol and cortisone indicating a rapid transfer of free cortisol in 
serum to saliva. We demonstrated the same Tmax for both serum cortisol and salivary cortisol 
indicating that movement of free cortisol from serum to saliva is very rapid. The modal Tmax for 
salivary cortisone was 10 minutes later than for salivary cortisol and could relate to conversion of 
salivary cortisol to salivary cortisone by 11β-HSD-2.  
 Salivary cortisone was higher at baseline and throughout the synacthen test than salivary 
cortisol. Salivary cortisol was <0.8 nmol/L in 62 (16.2%) of samples and salivary cortisone only in a 
single sample. This may be explained by the rapid conversion of free cortisol to salivary cortisone in 
the salivary gland 12. At baseline, before synacthen administration, serum cortisol and salivary 
cortisone exhibited a tight correlation (r=0.94), while serum cortisol and salivary cortisol were poorly 
correlated (r=0.45). This relates to the number of baseline salivary cortisol samples of <0.8 nmol/L 
excluded from analysis.  
 Following administration of synacthen the correlation between serum cortisol and both 
salivary cortisol and cortisone fell below 0.8 until the 50 minute sampling time point. Salivary cortisone 
is a product of both enzymatic conversion of salivary cortisol by 11β-HSD-2 and passive diffusion of 
free serum cortisone into saliva. Our results show that, with frequent sampling, under stimulated 
conditions, salivary cortisol and salivary cortisone correlate poorly with serum cortisol in the early 
dynamic phase of the synacthen test. This may reflect a lag between conversion of salivary cortisol to 
cortisone by 11β-HSD-2 but there is no evidence of enzymatic saturation. A previous study of salivary 
cortisol and salivary cortisone following 250 mcg synacthen demonstrated that free serum cortisone 
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did not rise in response to stimulation and had no influence on salivary cortisone fluctuations 12. The 
challenges of obtaining accurately paired salivary and blood samples, performed at very close 
intervals in order to model the pharmacodynamics of the response to synacthen, may also give rise to 
a reduced correlation, most obvious during the early frequent sampling times.  
 The mixed effects model for serum cortisol and salivary cortisone applied to our data is 
similar to that previously published 11. The line intercepts are the same (our data 1.23, published 
model 1.24) but slopes differ by a small degree (our data 0.823, published model 0.981, p<0.001) 11. 
The difference may reflect the different assay techniques employed to quantify serum cortisol 27. The 
published model used LC/MS-MS where in this study we used an immunoassay 11.   
The limitations of this study include: (i) the study was carried out on healthy individuals, (ii) 
that dexamethasone administration may interfere with the interpretation of the test, (iii) broad-based 
assay and test validation is necessary prior to introducing this methodology into clinical practice, (iv) 
our study used measurement of serum cortisol by immunoassay rather than LCMS, and (v) we didn’t 
measure serum levels of free cortisol or cortisone. However, our results relating the serum with 
salivary measurements fit with the previous literature, the strong correlation between free serum 
cortisol and salivary cortisol has been extensively reported 11,12, as has the lack of rise of serum free 
cortisone following synacthen 12. The use of healthy volunteers has the advantage of a very tightly 
controlled study with a uniform population of subjects. Further work is required to demonstrate 
whether similar responses are seen using different assay platforms, in non-dexamethasone 
suppressed individuals and those with adrenocortical insufficiency.  
Our results indicate that salivary cortisone reflects the serum cortisol response to synacthen 
but suggest that a 60 minute sample would be best used for diagnostic accuracy. However, before 
advocating replacement of a serum-based cortisol assay for cortisol quantification following synacthen 
administration, further studies are required in patient populations, without dexamethasone 
suppression and using LCMS in order to confirm our findings and define normal ranges of salivary 
cortisone and the diagnostic cutoffs for adrenal insufficiency.  
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Table  
Table 1. Median peak plasma cortisol and salivary cortisol and cortisone concentrations (Cmax) and 
time to Cmax (Tmax) following administration with low dose (1 mcg) and high dose (250 mcg) 
synacthen. 
 
 Serum cortisol Salivary cortisol Salivary cortisone 
Synacthen dose 1 mcg 250 mcg 1mcg 250 mcg 1 mcg 250 mcg 
Median Cmax 
(IQR) in mcg/dL 
(nmol/L) 
14 (386) 
(12-16)  
(333-430) 
22 (615) 
(21–24) 
(583-647) 
0.3 (7.3) 
(0.2-0.5) 
(5.1-12.9) 
1.2 (32.9) 
(1.0-1.3) 
(28.6-35.0) 
1.1 (31.4) 
(0.9-1.6) 
(24.4-42.7) 
2.8 (75.9) 
(2.6-3.0) 
(71.8-82.0) 
Modal Tmax in 
minutes 
30 120* 30 120* 40 120* 
* final sampling time point – Cmax may be beyond this and therefore Tmax later. 
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Figure legends 
 
Figure 1. Serum cortisol, salivary cortisol and salivary cortisone responses from baseline to 120 
minutes following administration with low dose (1 mcg) and high dose (250 mcg) synacthen. 
Individual, mean and mean +/- 1 standard deviation shown. 
 
Figure 2. (a), Scatter graph showing relation of serum cortisol to salivary cortisol by time after 
synacthen administration (intercept 2.17, slope 0.387). (b), Scatter graph showing relation of serum 
cortisol to salivary cortisone by time after synacthen administration. The mixed effects model line is 
shown in both (salivary cortisone intercept 1.23, slope 0.823), but for both salivary cortisol and 
cortisone the model does not include the time points between after time zero and before 60 minutes, 
as it is evident there is a lag in salivary response with these points falling above the model line. 
 
Figure 3. Serum cortisol plotted against salivary cortisone at each time point from baseline (-1 
minute) to 120 minutes following synacthen administration. The mixed effects model line is shown at 
each time point.  
 
Figure 4. (a), Correlation coefficients of serum cortisol and salivary cortisol at each time point 
following synacthen administration (correlation coefficients for -1, 5 and 10 minute samples not 
significant). (b), Correlation coefficients of serum cortisol and salivary cortisone at each time point 
following synacthen administration.   
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